Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Raw Materials (2016 - 2018)

Historic Raw Materials for Teva Pharmaceutical Industries (TEVJF) over the last 9 years, with Q4 2018 value amounting to $1.3 billion.

  • Teva Pharmaceutical Industries' Raw Materials fell 866.57% to $1.3 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $1.3 billion, marking a year-over-year decrease of 866.57%. This contributed to the annual value of $1.3 billion for FY2018, which is 866.57% down from last year.
  • Teva Pharmaceutical Industries' Raw Materials amounted to $1.3 billion in Q4 2018, which was down 866.57% from $1.4 billion recorded in Q3 2018.
  • Teva Pharmaceutical Industries' Raw Materials' 5-year high stood at $1.5 billion during Q1 2018, with a 5-year trough of $1.2 billion in Q4 2015.
  • In the last 5 years, Teva Pharmaceutical Industries' Raw Materials had a median value of $1.4 billion in 2016 and averaged $1.4 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Raw Materials tumbled by 1884.52% in 2014 and then skyrocketed by 1589.96% in 2016.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Raw Materials stood at $1.3 billion in 2014, then decreased by 6.57% to $1.2 billion in 2015, then increased by 15.9% to $1.4 billion in 2016, then rose by 4.98% to $1.5 billion in 2017, then dropped by 8.67% to $1.3 billion in 2018.
  • Its last three reported values are $1.3 billion in Q4 2018, $1.4 billion for Q3 2018, and $1.4 billion during Q2 2018.